ArticleJAC-antimicrobial resistance2020
CON: COVID-19 will not result in increased antimicrobial resistance prevalence.
Article in JAC-antimicrobial resistance, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 3 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Antibiotic resistance associated with the COVID-19 pandemic: a systematic review and meta-analysis.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2023Pooled it
- The challenge of preventing and containing outbreaks of multidrug-resistant organisms and Candida auris during the coronavirus disease 2019 pandemic: report of a carbapenem-resistant Acinetobacter baumannii outbreak and a systematic review of the literature.Antimicrobial resistance and infection control · 2022Pooled it
- Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2021Pooled it
- COVID-19 impact on AMR: a rapid scoping review, equity analysis and evidence gap map study.BMJ global health · 2025Article
- Joint surveillance and correlation analysis of antimicrobial resistance and consumption of seven targeted bacteria, 2017-2023.Scientific reports · 2025Article
- Three-year impact of COVID-19 pandemic on hospitalized twin pregnancies: evaluation of characteristics and changes in antibiotic prescribing.Frontiers in medicine · 2025Article
- Rebound of Antibiotic Use and Respiratory Infections After Resumption of Normalcy From COVID-19 in Hong Kong.Infection and drug resistance · 2025Article
- Risk factors for Carbapenem-resistantFrontiers in microbiology · 2025Article
- A scoping review of bacterial resistance among inpatients amidst the COVID-19 pandemic.Journal of global antimicrobial resistance · 2024Article
- COVID-19 restrictions limited interactions of people and resulted in loweredJAC-antimicrobial resistance · 2024Article
- Treatment seeking and antibiotic use for urinary tract infection symptoms in the time of COVID-19 in Tanzania and Uganda.Journal of global health · 2024Article
- A COVID-19 Silver Lining-Decline in Antibiotic Resistance in Ischemic Leg Ulcers during the Pandemic: A 6-Year Retrospective Study from a Regional Tertiary Hospital (2017-2022).Antibiotics (Basel, Switzerland) · 2023Article
- Microbiological profile of multidrug resistant bacteria before and during COVID-19 in CHU Mohammed VI.Iranian journal of microbiology · 2023Article
- Antimicrobial prescribing in a secondary care setting during the COVID-19 pandemic.JAC-antimicrobial resistance · 2023Article
- Leveraging the COVID-19 pandemic as a natural experiment to assess changes in antibiotic use and antibiotic-resistant E. coli carriage in semi-rural Ecuador.Scientific reports · 2023Observational
- Bacterial Pathogens and Antimicrobial Susceptibility Patterns of Urinary Tract Infections in Children during COVID-19 2019-2020: A Large Tertiary Care Center in Saudi Arabia.Children (Basel, Switzerland) · 2023Article
- Flare of the silent pandemic in the era of the COVID-19 pandemic: Obstacles and opportunities.World journal of clinical cases · 2023Review
- Trends in the Rates of Extended-Spectrum-β-Lactamase-ProducingMicrobiology spectrum · 2023Article
- Antibiotic resistance and consumption before and during the COVID-19 pandemic in Valle del Cauca, Colombia.Revista panamericana de salud publica = Pan American journal of public health · 2023Article
- Antimicrobial resistance pattern in clinicalGerms · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance (AMR) is affected by many factors, but too much of our focus has been on antimicrobial usage. The major factor that drives resistance rates globally is spread. The COVID-19 pandemic should lead to improved infection prevention and control practices, both in healthcare facilities and the community. COVID-19 will also have ongoing and profound effects on local, national and international travel. All these factors should lead to a decrease in the spread of resistant bacteria. So overall, COVID-19 should lead to a fall in resistance rates seen in many countries. For this debate we show why, overall, COVID-19 will not result in increased AMR prevalence. But globally, changes in AMR rates will not be uniform. In wealthier and developed countries, resistance rates will likely decrease, but in many other countries there are already too many factors associated with poor controls on the spread of bacteria and viruses (e.g. poor water and sanitation, poor public health, corrupt government, inadequate housing, etc.). In these countries, if economies and governance deteriorate further, we might see even more transmission of resistant bacteria.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.